First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication.

N Engl J Med

From the Office of Hematology and Oncology Products (S.L., P.K.) and the Oncology Center of Excellence (R.P.), Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD.

Published: October 2017

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMp1709968DOI Listing

Publication Analysis

Top Keywords

fda approval
4
approval agnostic
4
agnostic cancer
4
cancer site
4
site biomarker
4
biomarker defines
4
defines indication
4
fda
1
agnostic
1
cancer
1

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!